Antitrust law is often described as the referee of the marketplace. It does not care whether the players wear suits, scrubs, lab coats, or very expensive consultant sneakers. Its job is to ask whether competition was harmed and whether the right plaintiff is in court to complain about it. A recent Sixth Circuit decision in Academy of Allergy & Asthma in Primary Care v. Amerigroup Tennessee, Inc. puts that second question under a bright spotlight.
The case involved allergy testing, immunotherapy services, primary-care physicians, insurers, alleged boycotts, reimbursement disputes, and a business model that tried to bring allergy care closer to patients. That is already enough moving parts to make a legal department reach for coffee. But the decisive antitrust issue was not whether the alleged conduct sounded serious. It was whether the plaintiff, United Allergy Services, was directly enough injured to seek federal antitrust damages.
The Sixth Circuit answered no. The court held that United Allergy’s alleged injuries were too indirect because the insurers dealt directly with the physicians, while United Allergy supplied services to those physicians. In antitrust terms, United Allergy was treated as an indirect seller, two steps removed from the alleged antitrust violators. That distinction may sound technical, but in private antitrust litigation, technical details can decide the whole game before the jury ever gets a jersey.
What the Sixth Circuit Case Was About
United Allergy Services, operating through United Biologics, offered a model that helped primary-care physicians provide allergy testing and allergen immunotherapy. Rather than sending every patient to a specialist allergy clinic, participating physicians could use United Allergy’s equipment, technicians, supplies, and support to provide services in their own practices.
United Allergy alleged that this model disrupted the Tennessee allergy-care market. According to its allegations, the established allergy provider and several payors viewed the model as a threat. The company claimed that insurers and market incumbents coordinated audits, reimbursement restrictions, claim denials, and pressure campaigns that caused physicians to abandon United Allergy’s program. United Allergy framed the conduct as both a group boycott and price-fixing activity that reduced competition, restricted output, and harmed patients, particularly those in rural areas where access to allergy specialists may be limited.
The lawsuit included federal antitrust claims under Sections 1 and 2 of the Sherman Act, along with state-law claims such as tortious interference and civil conspiracy. The district court dismissed the federal antitrust claims, and the Sixth Circuit affirmed. The appellate court did not need to resolve every possible antitrust issue because one issue was enough: proximate causation.
The Decisive Question: Who Was Directly Harmed?
Private antitrust plaintiffs cannot sue merely because they were disappointed, disrupted, or financially hurt by conduct that may have affected a market. Under federal antitrust law, a plaintiff must show an antitrust injury and that the defendant’s unlawful conduct proximately caused that injury. In plain English: the plaintiff must be the right kind of victim, not just a bystander hit by marketplace shrapnel.
The Sixth Circuit reasoned that the physicians were the direct parties in the reimbursement relationship with the insurers. The insurers allegedly reduced payments, denied claims, or pressured physicians. United Allergy’s injury flowed from what happened next: physicians did not pay United Allergy’s fees, ended relationships, or stopped offering the services. That made the injury derivative. The court’s message was simple enough to fit on a compliance sticky note: follow the money, follow the contracts, and follow the immediate injury.
That is why the court focused on proximate causation rather than spending most of its energy on whether United Allergy suffered an antitrust injury. Even assuming the company suffered harm connected to competition, the alleged harm was not direct enough to support federal damages.
Why Illinois Brick Still Matters
The decision draws heavily from the long-running federal rule associated with Illinois Brick Co. v. Illinois. That rule generally bars indirect purchasers from recovering federal antitrust damages when they are too far removed from the alleged violator in a distribution chain. The policy reason is not exactly glamorous, but it is powerful: courts want to avoid duplicative recovery, speculative damages calculations, and complicated pass-on theories that require judges to become amateur economists with headaches.
The companion idea comes from Hanover Shoe, where the Supreme Court limited the ability of antitrust defendants to argue that direct purchasers suffered no damages because they passed overcharges downstream. Together, Hanover Shoe and Illinois Brick create a federal damages structure that usually concentrates recovery in the hands of direct purchasers.
The Sixth Circuit applied that logic in reverse. If indirect purchasers are typically barred when they are too far downstream, then indirect sellers may also be barred when they are too far upstream from the alleged antitrust-violating buyers. In this case, United Allergy sold services to physicians; physicians sought reimbursement from insurers; the insurers were the alleged antitrust violators. To the court, that made United Allergy two steps removed.
Boycott, Price Fixing, Lost Profits: Why Labels Did Not Save the Claim
One of the most important parts of the Sixth Circuit decision is its rejection of label-based pleading. United Allergy argued that its case was not a classic overcharge case. It alleged a boycott and sought lost profits, not merely repayment of passed-on price increases. That distinction matters in everyday language. In antitrust doctrine, however, the court said the directness problem remained.
The court viewed the Illinois Brick rule as plaintiff-specific, not damages-specific. In other words, the question was not only, “What kind of damages are you requesting?” The bigger question was, “Where do you sit in the chain of commerce?” If the plaintiff is indirect, calling the conduct a boycott rather than a cartel may not cure the problem.
That holding is a practical warning for antitrust plaintiffs. A complaint cannot rely on dramatic vocabulary alone. Words like “boycott,” “cartel,” “monopoly,” and “market exclusion” are serious, but they are not magic spells. Courts still ask whether the plaintiff is directly connected to the challenged transaction and whether other parties are better positioned to sue.
Antitrust Standing Is Not Ordinary Standing
Businesses often hear the word “standing” and think it simply means the plaintiff was harmed. Antitrust standing is more demanding. A company can suffer real economic harm and still fail to qualify as a proper federal antitrust plaintiff.
The doctrine looks at factors such as the nature of the injury, the directness of the harm, the risk of duplicate recovery, the existence of more direct victims, and whether damages would be too speculative. This is why antitrust cases can feel like a legal obstacle course. The plaintiff must not only allege bad conduct and market harm; it must also show that it is the right party to recover under the statute.
The Sixth Circuit’s approach lines up with broader Supreme Court guidance that statutory causes of action do not automatically extend to every party who can trace some harm to alleged misconduct. Courts often require a closer causal relationship between the violation and the injury. In this case, that requirement did most of the work.
Why the Decision Matters for Healthcare Markets
The healthcare context makes the decision especially interesting. Modern healthcare markets are rarely simple two-party transactions. Patients, providers, insurers, third-party administrators, government programs, technicians, labs, platforms, and management companies may all participate in a single service pathway. If antitrust liability depends heavily on directness, companies operating in healthcare networks need to map relationships carefully.
For innovators, the case is sobering. A company may believe it is the true target of exclusionary conduct, especially if competitors and payors appear to be pushing customers away from its model. But if the challenged payments or denials occur between other parties, the innovator may face a directness problem when seeking federal damages.
For insurers and established providers, the decision offers a potential defense roadmap. If a plaintiff’s losses depend on decisions made by intermediate physicians, clinics, or customers, defendants may argue that causation is too attenuated. That does not mean every such case fails. It does mean plaintiffs must be ready to prove why their injury is not merely derivative.
The Debate Over Formalism and Market Reality
The case also produced debate within the Sixth Circuit. The denial of rehearing en banc drew attention because some judges questioned whether the panel’s approach was too formalistic. The concern was that United Allergy and the physicians may have functioned more like joint participants in a service model than like a traditional supplier and reseller.
That concern is not trivial. Business models today often blend roles. A platform may be a retailer, marketplace, payment processor, and gatekeeper all at once. A healthcare services company may supply equipment and technicians while participating deeply in the delivery of care. A software provider may be both vendor and ecosystem partner. The old-fashioned image of a manufacturer selling widgets to a wholesaler selling widgets to a retailer selling widgets to a consumer does not always fit the modern economy.
Still, the panel decision remains important because it shows the continuing force of bright-line rules. Courts often prefer administrable boundaries, especially in damages cases. Bright lines may occasionally feel blunt, but they reduce uncertainty, prevent overlapping claims, and keep antitrust litigation from becoming a never-ending family reunion of everyone indirectly affected by a market event.
Lessons for Plaintiffs: Build the Case Before Filing
1. Map the Distribution Chain Early
Before filing an antitrust complaint, plaintiffs should draw the commercial chain on paper. Who sold what to whom? Who paid whom? Who denied payment? Who lost sales first? If the diagram starts looking like a subway map after a thunderstorm, causation may become the central issue.
2. Identify the Best Plaintiff
The most injured business is not always the best antitrust plaintiff. The direct purchaser, direct seller, or direct competitor may be better positioned to sue. In some cases, a company may need to coordinate with customers, providers, or other market participants whose injuries are more direct.
3. Do Not Rely on Legal Labels Alone
Calling conduct a boycott or price-fixing conspiracy is not enough. Plaintiffs should explain precisely how the conduct harmed competition, why the plaintiff’s injury is direct, and why damages can be calculated without speculation or duplication.
4. Preserve Evidence of Causation
Emails, contract notices, payment records, termination letters, reimbursement data, and customer statements can matter. Courts want more than a plausible business narrative. They want a causal bridge sturdy enough to walk across without falling into a swamp of assumptions.
Lessons for Defendants: Directness Can Be a Powerful Defense
For defendants, the Sixth Circuit decision reinforces the value of early motion practice. If the complaint shows that the plaintiff is upstream or downstream from the direct transaction, defendants may be able to challenge antitrust standing and proximate causation at the pleading stage.
Defendants should also avoid turning a strong directness defense into a public-relations disaster. In sensitive sectors like healthcare, arguing that a plaintiff is too indirect does not necessarily answer broader concerns about patient access or market fairness. A legal win may still require careful messaging, compliance review, and business discipline.
What Businesses Should Watch Next
The ruling matters beyond allergy care. It may influence disputes involving platform markets, healthcare networks, franchise systems, supply-chain boycotts, insurance reimbursement models, and data-driven service ecosystems. Wherever there are multiple commercial layers, plaintiffs and defendants will likely argue about who sits close enough to the alleged violation.
The decision also keeps alive a broader question: should federal antitrust law adapt its directness rules to modern joint-service models, or should bright-line rules remain strict to prevent speculative damages? That question is not going away. The economy keeps inventing business models faster than legal doctrines can update their wardrobes.
Experience-Based Takeaways: What Antitrust Teams Learn the Hard Way
In practical antitrust work, the hardest lesson is often that “unfair” and “actionable” are not the same word. Business leaders may see a competitor whispering to customers, a payor changing reimbursement rules, or a partner walking away after pressure from a powerful market player and immediately conclude that antitrust law must provide a remedy. Sometimes it does. Sometimes it does not. The difference usually turns on structure, evidence, and causation.
One common experience in disputes like this is the late discovery that the commercial relationship was never documented with litigation in mind. Contracts may describe a vendor relationship even though the parties operationally behave like partners. Marketing materials may call the arrangement a collaboration, while invoices make it look like a routine supply deal. When a court must classify the relationship, those documents can matter more than the business team expected. The lesson is simple: if a business model depends on joint value creation, the paperwork should reflect that reality clearly and consistently.
Another recurring experience is that damages theories often become more fragile under pressure. Lost profits may feel obvious to the injured company: customers left, invoices went unpaid, revenue fell, and the alleged misconduct happened in the same period. But courts usually ask a tougher question. Did the defendant’s anticompetitive conduct directly cause those losses, or could customers have left because of reimbursement uncertainty, regulatory concerns, operational friction, pricing, quality issues, or ordinary business risk? If the answer requires too many assumptions, the claim can wobble.
Healthcare disputes add even more complexity because payors, providers, patients, and service companies all have overlapping incentives. A reimbursement decision may look anticompetitive to one party and medically or contractually justified to another. A specialist group may view a new model as unsafe or noncompliant, while the innovator views that criticism as exclusionary. The courtroom then becomes the place where business strategy, medical judgment, contract interpretation, and antitrust doctrine all attempt to sit at the same conference table. It is a crowded table, and someone always spills the coffee.
The Sixth Circuit decision shows why early legal assessment is essential. Before sending a demand letter or filing a complaint, companies should test the case from the judge’s perspective. Who is the direct buyer or seller? Who absorbed the first economic hit? Are there more direct plaintiffs? Would damages overlap? Can the company show specific customers were lost because of the alleged conduct rather than because of independent decisions? These questions are not academic. They may determine whether the case survives.
For companies worried about being excluded from a market, the best experience-based advice is to build a record in real time. Track customer communications. Save reimbursement data. Document changes in policy. Record why customers terminate or reduce business. Keep compliance reviews current. And when possible, design contracts that accurately describe the economic role each party plays. Antitrust cases are rarely won by outrage alone. They are won by clean facts, strong causation, and a plaintiff who belongs in the direct lane.
Conclusion
The Sixth Circuit decision highlights a decisive antitrust issue that every business should understand: the right plaintiff matters as much as the alleged wrongdoing. United Allergy alleged serious competitive harm, including coordinated reimbursement restrictions and a campaign that pushed physicians away from its model. But the court held that its federal antitrust damages claims failed because its injuries were too indirect.
For plaintiffs, the ruling is a reminder to build antitrust claims around direct injury, not just market frustration. For defendants, it reinforces the importance of proximate causation and the indirect purchaser and indirect seller doctrines. For everyone else, it proves that antitrust law is not merely about spotting bad behavior; it is about tracing harm through the marketplace with precision.
Note: This article is for general informational and SEO publishing purposes only. It is not legal advice, and businesses facing antitrust questions should consult qualified counsel.
